吉非替尼联合贞芪扶正胶囊治疗老年人中晚期非小细胞肺癌的临床观察

摘要

Objective To evaluate the clinical efficacy and toxicity of gefitinib combined with Zhenqi Fuzheng capsule in treatment of senile non-small-cell lung cancer (NSCLC) at the middle and late stages. Methods 88 patients with NSCLC at Ⅲ b-Ⅳ were randomly divided into combined drugs group ( gefitinib combined Zhenqi Fuzheng capsule,n =46 cases) and single drug group (gefitinib,n=42 cases).After treatment for 60 d,the short-term efficacy,side effects and quality of life were observed and evaluated. The objective response and survival rate were assessed after following up for 2 years. Results The short-term efficacy rate in the combined drugs group (19.6 ％ ) was higher than single drug group (11.9 ％ ),but there was no significant difference between the two groups (x2=0.096,P＞0.05).The rate of Karnofsky score in improvement and stableness was 71.7％ in combined drugs group and 50.0％ in single drug group,and quality of life improved after combined drugs compared with single drug treatment (x2 =4.376,P＜0.05).The adverse effects in combined drugs group was some lower than in single drug group with no statistical significance.There was no differences in the survival rates of 2 years between the two groups(x2 =0.556,P＞0.05). Conclusions The gefitinib combined Zhenqi Fuzheng capsule in treatment of middle-and late-stage NSCLC is worthy to be popularized due to positive efficacy,less side effects and higher quality of life.%目的 观察吉非替尼联合贞芪扶正胶囊治疗老年人中晚期非小细胞肺癌( NSCLC)的临床疗效和不良反应. 方法 88例Ⅲb～Ⅳ期NSCLC患者随机分为联合组(46例)和单药组(42例).联合组采用吉非替尼联合贞芪扶正胶囊治疗,单药组采用吉非替尼治疗.治疗60 d后,观察两组近期疗效、不良反应及评价生活质量,随访2年评价客观疗效和生存率. 结果 联合组近期疗效有效率为19.6％,单药组为11.9％,差异无统计学意义(x2=0.096,P＞0.05).联合组Karnofsky计分提高和稳定者71.7％,单药组50.0％,联合组生活质量改善高于单药组(x2=4.376,P＜0.05)；与单药组相比,联合组不良反应发生率稍低于单药组,差异无统计学意义；两组2年生存率未见显著性差异(x2 =0.556,P＞0.05). 结论 吉非替尼联合贞芪扶正胶囊治疗中晚期NSCLC临床疗效肯定,不良反应小,生活质量改善明显,值得临床推广.